Chemokines and cancer: new immune checkpoints for cancer therapy

被引：110

作者：

Karin, Nathan ^{[1
]}

机构：

[1] Technion Israel Inst Technol, Dept Immunol, Fac Med, POB 9697, IL-31096 Haifa, Israel

来源：

CURRENT OPINION IN IMMUNOLOGY | 2018年 / 51卷

基金：

以色列科学基金会;

关键词：

REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TUMOR-IMMUNITY; COLORECTAL-CANCER; BREAST-CANCER; LUNG-CANCER; REG CELLS; CXCL10; RECEPTORS; NIVOLUMAB;

D O I：

10.1016/j.coi.2018.03.004

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The current review focuses on two chemokine-chemokine receptor interactions: CXCL10-CXCR3 and CCL1-CCR8. We show that CXCL10 acts on CD4+ and CD8+ T cells to enhance anti-tumor immunity, and explore the translational perspectives of these findings. As for CCR8 very recently, we identified a novel subset of CCR8+CD4+FOXp3+ regulatory T cells (T-reg) that are major drivers of immune regulation. We observed that one of the four CCR8 ligands, CCL1, produced by these cells, potentiates their suppressive activity via induction of CCR8, FOXp3, CD39, Granzyme-B, and IL-10 in a positive feedback mechanism, making them master drivers of immune regulation. Collectively, this suggests blocking the CCR8-CCL1 interaction, alone or combined with other immune checkpoint inhibitors, as an approach to treat malignant diseases.

引用

页码：140 / 145

页数：6

共 53 条

[1] Improved survival in tumor-bearing SCID mice treated with interferon-γ-inducible protein 10 (IP-10/CXCL10) [J].

Arenberg, DA ;

White, ES ;

Burdick, MD ;

Strom, SRB ;

Strieter, RM .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2001, 50 (10) :533-538

[2] Heparanase enhances myeloma progression via CXCL10 downregulation [J].

Barash, U. ;

Zohar, Y. ;

Wildbaum, G. ;

Beider, K. ;

Nagler, A. ;

Karin, N. ;

Ilan, N. ;

Vlodavsky, I. .

LEUKEMIA, 2014, 28 (11) :2178-2187

[3] CCR8+FOXp3+ Treg cells as master drivers of immune regulation [J].

Barsheshet, Yiftah ;

Wildbaum, Gizi ;

Levy, Eran ;

Vitenshtein, Alon ;

Akinseye, Chika ;

Griggs, Jeremy ;

Lira, Sergio A. ;

Karin, Nathan .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (23) :6086-6091

[4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[6] Stromal derived factor 1α: A chemokine that delivers a two-pronged defence of the myocardium [J].

Bromage, Daniel I. ;

Davidson, Sean M. ;

Yellon, Derek M. .

PHARMACOLOGY & THERAPEUTICS, 2014, 143 (03) :305-315

[7] CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer [J].

Bronger, Holger ;

Singer, Judith ;

Windmueller, Claudia ;

Reuning, Ute ;

Zech, Daniela ;

Delbridge, Claire ;

Dorn, Julia ;

Kiechle, Marion ;

Schmalfeldt, Barbara ;

Schmitt, Manfred ;

Avril, Stefanie .

BRITISH JOURNAL OF CANCER, 2016, 115 (05) :553-563

[8] CTLA-4 and PD-1 pathway blockade: combinations in the clinic [J].

Callahan, Margaret K. ;

Postow, Michael A. ;

Wolchok, Jedd D. .

FRONTIERS IN ONCOLOGY, 2015, 4

[9] Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice [J].

Chensue, SW ;

Lukacs, NW ;

Yang, TY ;

Shang, XZ ;

Frait, KA ;

Kunkel, SL ;

Kung, T ;

Wiekowski, MT ;

Hedrick, JA ;

Cook, DN ;

Zingoni, A ;

Narula, SK ;

Zlotnik, A ;

Barrat, FJ ;

O'Garra, A ;

Napolitano, M ;

Lira, SA .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (05) :573-584

[10] CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease [J].

Coghill, James M. ;

Fowler, Kenneth A. ;

West, Michelle L. ;

Fulton, LeShara M. ;

van Deventer, Hendrik ;

McKinnon, Karen P. ;

Vincent, Benjamin G. ;

Lin, Kaifeng ;

Panoskaltsis-Mortari, Angela ;

Cook, Donald N. ;

Blazar, Bruce R. ;

Serody, Jonathan S. .

BLOOD, 2013, 122 (05) :825-836

← 1 2 3 4 5 6 →